News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Global Pharmaceutical Company Licenses Ajinomoto's Corynex™ Recombinant Protein Expression System Following Successful Proof-of-Concept



3/5/2013 9:32:57 AM

RALEIGH, N.C.--(BUSINESS WIRE)--Ajinomoto North America, Inc. today announced a top-tier, global pharmaceutical company has licensed its CorynexTM Recombinant Protein Expression System. The pharma assessed the Technology with a number of recombinant proteins. Based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of Ajinomoto’s proprietary CorynexTM Expression. CorynexTM uses the gram-positive Corynebacterium glutamicum to reduce purification steps, lower costs, and increase yield. CorynexTM does not require cell lysis or protein refolding, eliminating the need for endotoxin removal steps. The system also speeds production through a fast-growing bacterial model, shorter fermentation run to produce proteins and cheaper bacterium medium cost.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES